Scientific Publications

Search by Keyword(s)
Found 5 results

Filters: Author is Liao, RG  [Clear All Filters]

Search Results

  • Showing 1-5 of 5 Results
2014
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Tan, L., Wang J., Tanizaki J., Huang Z., Aref AR, Rusan M., Zhu SJ, Zhang Y., Ercan D., Liao RG, Capelletti M., Zhou W., Hur W., Kim N., Sim T., Gaudet S., Barbie DA, Yeh JR, Yun CH, Hammerman PS, et al. Proceedings of the National Academy of Sciences of the United States of America, 2014/10/27, (2014) Read More / View Supplemental Materials
Abstract
Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC.Wong, KK, Tchaicha JH, Akbay EA, Altabef A., Mikse OR, Kikuchi E., Rhee K., Liao RG, Bronson RT, Sholl LM, Meyerson M., and Hammerman PS Cancer research, 2014/07/17, (2014) Read More / View Supplemental Materials
Abstract
Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.Wang, J., Mikse O., Liao RG, Li Y., Tan L., Janne PA, Gray NS, Wong KK, and Hammerman PS Oncogene, 2014/06/09, (2014) Read More / View Supplemental Materials
Abstract
2013
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Liao, RG, Jung J., Tchaicha JH, Wilkerson MD, Sivachenko A., Beauchamp EM, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G., Wong KK, Meyerson M., and Hammerman PS Cancer research, 2013/06/20, (2013) Read More / View Supplemental Materials
Abstract
2012
Targeted therapy for squamous cell lung cancer.Liao, RG, Watanabe H., Meyerson M., and Hammerman PS Lung cancer management, 2012/12/01, Volume 1, Issue 4, p.293-300, (2012) Read More / View Supplemental Materials
Abstract
  • Showing 1-5 of 5 Results